Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
DARUNAVIR
APOTEX INC
J05AE10
DARUNAVIR
600MG
TABLET
DARUNAVIR 600MG
ORAL
15G/50G
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0151656003; AHFS:
APPROVED
2020-01-02
_APO-DARUNAVIR (Darunavir Tablets) _ _Page 1 of 106_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-DARUNAVIR Darunavir Tablets Tablets, 600 mg and 800 mg, Oral Human Immunodeficiency Virus (HIV) Protease Inhibitor APOTEX INC. 150 Signet Drive Toronto, Ontario Canada, M9L 1T9 Date of Initial Authorization: JAN 02, 2020 Date of Revision: JUN 15, 2023 Submission Control Number: 271086 _APO-DARUNAVIR (Darunavir Tablets) _ _Page 2 of 106_ RECENT MAJOR LABEL CHANGES None at the time of the most recent authorization. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .................................................................................................................. 4 1.1 Pediatrics ...................................................................................................................... 4 1.2 Geriatrics ....................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ..................................................................................... 5 4.1 Dosing Considerations .................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ............................................................. 5 4.5 Missed Dose .................................................................................................................. 8 5 OVERDOSAGE .............. Կարդացեք ամբողջական փաստաթուղթը